Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity.
10.3341/kjo.2014.28.6.466
- Author:
Young Suk CHANG
1
;
Jung Il HAN
;
Su Jin YOO
;
Young Ju LEW
;
Jae Hui KIM
Author Information
1. Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea.
- Publication Type:Observational Study ; Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Anti-vascular endothelial growth factor;
Bevacizumab;
Good visual acuity;
Macular degeneration;
Ranibizumab
- MeSH:
Aged;
Angiogenesis Inhibitors/*therapeutic use;
Bevacizumab/therapeutic use;
Choroidal Neovascularization/*drug therapy/physiopathology;
Female;
Fluorescein Angiography;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Ranibizumab/therapeutic use;
Retrospective Studies;
Tomography, Optical Coherence;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity/*physiology;
Wet Macular Degeneration/*drug therapy/physiopathology
- From:Korean Journal of Ophthalmology
2014;28(6):466-472
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyes with typical exudative age-related macular degeneration with good baseline visual acuity. METHODS: This retrospective observational case series included 18 eyes (18 patients) with typical exudative age-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patients were treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months. RESULTS: Patients received an average of 4.4 +/- 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 +/- 0.04, 0.08 +/- 0.07, 0.12 +/- 0.09, and 0.16 +/- 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months was significantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness at the defined time points was 270.2 +/- 55.6, 204.4 +/- 25.4, 230.1 +/- 56.3, and 216.8 +/- 48.7 microm, respectively. The central foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042). CONCLUSIONS: Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degeneration with good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatment even in patients with good baseline visual acuity.
